Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
South Korea · Delayed Price · Currency is KRW 4,950.00
-70.00 (-1.39%)
At close: Jun 19, 2026
Seoulin Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 518.17 | 731.98 | 2,914 | -117.55 | 10,159 | 15,589 |
Depreciation & Amortization | 1,148 | 1,163 | 1,365 | 1,287 | 1,017 | 1,930 |
Loss (Gain) From Sale of Assets | 0 | 0 | 65.11 | 31.42 | 0.65 | -14,092 |
Asset Writedown & Restructuring Costs | 373.89 | 373.89 | 152.6 | - | 393.03 | 1,044 |
Loss (Gain) From Sale of Investments | 453.02 | 421.13 | -1,986 | 4,966 | -2,011 | -160.11 |
Loss (Gain) on Equity Investments | -21.51 | -7.53 | -139.95 | -85.1 | -84.76 | -114.5 |
Provision & Write-off of Bad Debts | 88.29 | 86.41 | 328.55 | -61.68 | 452.77 | 27.35 |
Other Operating Activities | -84.16 | -172.01 | 424.55 | 1,869 | -4,163 | 5,535 |
Change in Accounts Receivable | 1,074 | -743.12 | 5,504 | -6,269 | 3,048 | -1,314 |
Change in Inventory | -51.12 | 1,897 | -4,345 | -7,528 | -3,918 | -3,025 |
Change in Accounts Payable | 1,120 | 2,599 | -6,447 | 2,936 | -2,163 | 4,435 |
Change in Other Net Operating Assets | -3,261 | -1,590 | -2,447 | 3,903 | -7,086 | -938.58 |
Operating Cash Flow | 1,358 | 4,760 | -4,611 | 930.57 | -4,356 | 8,918 |
Operating Cash Flow Growth | - | - | - | - | - | 142.03% |
Capital Expenditures | -382.44 | -392.61 | -48.45 | -945.51 | -461.62 | -933.29 |
Sale of Property, Plant & Equipment | -0.33 | - | 0.49 | 123.75 | 59.86 | 20,418 |
Cash Acquisitions | - | - | - | - | -35.23 | - |
Divestitures | - | - | 0.08 | - | - | - |
Sale (Purchase) of Intangibles | -8.21 | -8.21 | -13.97 | - | -245.42 | -669.69 |
Sale (Purchase) of Real Estate | -106.66 | -106.66 | - | -28.7 | 4.97 | -66.82 |
Investment in Securities | -14,808 | -16,278 | 6,429 | 28,576 | -1,904 | -49,934 |
Other Investing Activities | -3.4 | -3.4 | -12.68 | -204.53 | -44.07 | -312.18 |
Investing Cash Flow | -15,309 | -16,789 | 6,389 | 27,526 | -2,665 | -31,499 |
Short-Term Debt Issued | - | - | 3,000 | 550.5 | 55.95 | 125.73 |
Long-Term Debt Issued | - | 18,270 | - | 0.13 | - | 30,000 |
Total Debt Issued | 18,270 | 18,270 | 3,000 | 550.63 | 55.95 | 30,126 |
Short-Term Debt Repaid | - | -3,050 | -50 | -40.18 | -35.27 | -38.5 |
Long-Term Debt Repaid | - | -172.63 | -8,475 | -22,083 | -296.05 | -229.77 |
Total Debt Repaid | -180.67 | -3,223 | -8,525 | -22,123 | -331.32 | -268.27 |
Net Debt Issued (Repaid) | 18,089 | 15,047 | -5,525 | -21,573 | -275.37 | 29,857 |
Repurchase of Common Stock | -59.56 | -59.56 | -1,092 | -142.62 | -198.94 | -80.6 |
Dividends Paid | -843.6 | -843.6 | -836.16 | -1,062 | -798.49 | -769.16 |
Other Financing Activities | -500 | -500 | - | -0 | 2,350 | -0 |
Financing Cash Flow | 16,686 | 13,644 | -7,453 | -22,778 | 1,077 | 29,008 |
Foreign Exchange Rate Adjustments | -111.7 | -111.7 | 22.54 | -75.93 | -30.2 | 47.83 |
Miscellaneous Cash Flow Adjustments | -0 | -0 | 0 | - | -0 | 0 |
Net Cash Flow | 2,623 | 1,503 | -5,653 | 5,603 | -5,974 | 6,475 |
Free Cash Flow | 975.2 | 4,367 | -4,660 | -14.95 | -4,817 | 7,984 |
Free Cash Flow Growth | - | - | - | - | - | 143.19% |
Free Cash Flow Margin | 1.24% | 5.67% | -6.18% | -0.02% | -4.60% | 9.91% |
Free Cash Flow Per Share | 101.02 | 453.09 | -535.72 | -1.67 | -432.86 | 887.61 |
Cash Interest Paid | 30.09 | 37.91 | 48.25 | 20.79 | 10.83 | 14.23 |
Cash Income Tax Paid | 173.11 | 64.08 | 1,295 | 1,408 | 5,837 | 668.25 |
Levered Free Cash Flow | 6,430 | 9,929 | -8,710 | -12,310 | -12,853 | 27,527 |
Unlevered Free Cash Flow | 7,037 | 10,332 | -8,504 | -10,759 | -11,424 | 27,667 |
Change in Working Capital | -1,118 | 2,163 | -7,735 | -6,958 | -10,119 | -841.77 |